Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/simvastatin versus high-dose simvastatin for postprandial endothelial function in metabolic syndrome
NL-OMON33868Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ezetimibe and simvastatin in cardiometabolic risk (CMR) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Postprandial flow-mediated dilation. Started Apr 2009; status: active, not recruiting.
02
Drugs
ezetimibesimvastatin
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON33868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33868.